Free Trial

Theralase Technologies (TLT) Stock Price, News & Analysis

-0.01 (-3.13%)
(As of 11:18 AM ET)
Today's Range
50-Day Range
52-Week Range
59,000 shs
Average Volume
120,408 shs
Market Capitalization
C$37.09 million
P/E Ratio
Dividend Yield
Price Target
TLT stock logo

About Theralase Technologies Stock (CVE:TLT)

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin - Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology that accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it researches, develops, manufactures, and distributes controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100 to healthcare practitioners primarily for the healing of pain. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. The company is based in Toronto, Canada.

TLT Stock Price History

TLT Stock News Headlines

Theralase(R) Expands Clinical Team
Theralase(R) Granted Canadian Cancer Vaccine Patent
Theralase Technologies Inc TLT
Theralase Release's 3Q2023 Interim Financial Statements
Theralase(R) Announces Brokered LIFE Financing
See More Headlines
Receive TLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theralase Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)

Industry, Sector and Symbol

Medical Devices
Year Founded


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
C$1.07 million
Cash Flow
C$0.01 per share
Book Value
C$0.01 per share


Free Float
Market Cap
C$38.29 million
Not Optionable
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Ms. Kristina Hachey CPA
    CFO & Director
  • Dr. Arkady Mandel DSc.
    M.D., Ph.D., Chief Scientific Officer & Director
  • Mr. Roger John Dumoulin-White B.Sc.
    P.Eng., President, CEO & Director
  • Mr. David M. Groves B.A
    President of World Trade Division
  • Dr. Terry Ruch DVM
    Equine Medical Consultant

TLT Stock Analysis - Frequently Asked Questions

How have TLT shares performed in 2024?

Theralase Technologies' stock was trading at C$0.18 on January 1st, 2024. Since then, TLT stock has decreased by 8.6% and is now trading at C$0.16.
View the best growth stocks for 2024 here

When is Theralase Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 4th 2024.
View our TLT earnings forecast

How were Theralase Technologies' earnings last quarter?

Theralase Technologies Inc. (CVE:TLT) released its quarterly earnings results on Wednesday, March, 27th. The company reported ($0.01) earnings per share for the quarter. The business had revenue of $0.36 million for the quarter.

Is Theralase Technologies a good dividend stock?

Theralase Technologies (CVE:TLT) pays an annual dividend of C$2.90 per share and currently has a dividend yield of 2.03%.

What other stocks do shareholders of Theralase Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Theralase Technologies investors own include IMRIS (IMRSQ), Cross Timbers Royalty Trust (CRT), Aurora Cannabis (ACB), AGNC Investment (AGNC), InfraCap MLP ETF (AMZA), Alliance Resource Partners (ARLP), Ford Motor (F), Gladstone Investment (GAIN) and Heat Biologics (HTBX).

How do I buy shares of Theralase Technologies?

Shares of TLT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (CVE:TLT) was last updated on 5/24/2024 by Staff

From Our Partners